VRE Form 144: 32,040 shares ($482,891) proposed sale; Sept affiliated stock disposals noted

Rhea-AI Filing Summary

Veris Residential, Inc. (VRE) filed a Form 144 proposing the sale of 32,040 common shares with an aggregate market value of $482,890.86. The shares represent part of the company's outstanding common stock of 93,421,769 shares and are expected to be sold on the NYSE approximately on 10/01/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services.

The filing shows the shares were acquired in open-market purchases in July 2018 (15,108 shares on 07/27/2018 and 16,932 shares on 07/25/2018) with cash payment. The notice also lists extensive prior sales during September 9–18, 2025 by related entities MIRELF VI REIT INVESTMENT II, LLC and MIRELF VII US SECURITIES LLC, indicating recent significant dispositions of common stock by affiliated sellers.

Positive

• Sale to be executed on NYSE via Morgan Stanley Smith Barney LLC supports orderly market execution
• Acquisition history documented: shares were purchased in open-market transactions in July 2018 and paid in cash

Negative

• Multiple sizable sales in Sept 2025 by affiliated entities (MIRELF VI and MIRELF VII) indicate recent significant dispositions that may increase supply
• Form 144 provides no context on purpose of sale (e.g., diversification, liabilities), limiting insight into seller motivation

Insights

Securities Analyst

TL;DR: Routine Rule 144 sale notice for 32,040 VRE shares to be executed on NYSE; acquisition from open-market in 2018; recent affiliated sales in September 2025 are notable.

The filing is a standard compliance notice under Rule 144 documenting a proposed sale of restricted/controlled securities. The seller acquired the shares in two open-market purchases in July 2018 and intends to sell through a major broker-dealer, which supports orderly execution. The list of multiple, sizable sales by MIRELF VI and MIRELF VII during September 9–18, 2025 suggests affiliated entities have been actively liquidating position(s) recently; this is relevant for short-term supply dynamics but requires cross-checking with total issuer float to assess impact. Overall, the disclosure itself is procedural rather than information-altering about the issuer's operations.

Corporate Governance Specialist

TL;DR: Filing meets Rule 144 disclosure requirements; the representation about no undisclosed material adverse information is standard and important for compliance.

The signed representation that the seller is unaware of any undisclosed material adverse information is a formal and required attestation. The presence of repeated sizable sales by affiliated entities in September 2025 could merit governance review by stakeholders to confirm these dispositions align with any lock-up or insider trading plans. However, the Form 144 does not provide evidence of misconduct or issuer-specific operational issues; it documents planned and completed sales and acquisition details only.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	32040	482890.86	93421769	10/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/27/2018	Open Market Purchase	Open Market			15108	07/27/2018	Cash
Common	07/25/2018	Open Market Purchase	Open Market			16932	07/25/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/18/2025	41018	634413.10
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/18/2025	30592	473157.29
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/17/2025	14989	232632.28
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/17/2025	20097	311909.46
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/16/2025	40355	622601.54
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/16/2025	54108	834784.42
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/15/2025	26600	416276.70
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/15/2025	19838	310454.78
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/12/2025	79724	1272734.52
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/12/2025	106897	1706531.26
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/11/2025	85440	1373003.71
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/11/2025	114560	1840956.29
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/10/2025	85920	1378491.89
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/10/2025	64080	1028093.11
MIRELF VI REIT INVESTMENT II, LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/09/2025	64080	1032924.74
MIRELF VII US SECURITIES LLC Harborside 3, 210 Hudson St. Ste. 400 Jersey City NJ 07311	Common	09/09/2025	85920	1384970.29

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Veris Residential's (VRE) Form 144 propose?

The Form 144 proposes the sale of 32,040 common shares of VRE with an aggregate market value of $482,890.86, to be sold on the NYSE approximately on 10/01/2025.

How and when were the shares being sold acquired?

The shares were acquired in open-market purchases on 07/25/2018 (16,932 shares) and 07/27/2018 (15,108 shares), with cash payment.

Who is the executing broker for the proposed sale?

The sale is listed to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, New York, NY.

Were there recent related sales by affiliated entities?

Yes. The filing lists multiple sales by MIRELF VI REIT INVESTMENT II, LLC and MIRELF VII US SECURITIES LLC between September 9 and September 18, 2025, totaling many tens of thousands of shares across that period.

Does the Form 144 provide any operational or earnings information about VRE?

No. The Form 144 only discloses proposed securities sales and acquisition/payment details and includes a standard attestation regarding undisclosed material adverse information.